{"id":"bl-b01d1-for-injection","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"However, the exact mechanism of action is not well-documented, and further research is needed to fully understand its effects.","oneSentence":"BL-B01D1 for Injection is a drug that works by targeting a specific molecular pathway.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:24:41.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 2 clinical trials for BL-B01D1 for Injection are ongoing, but specific indications are not publicly available."}]},"trialDetails":[{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT05785039","phase":"PHASE2","title":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-04-20","conditions":"Urinary System Tumor, Solid Tumor","enrollment":76},{"nctId":"NCT05803018","phase":"PHASE1, PHASE2","title":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-06-25","conditions":"Gynecological Malignant Tumor, Solid Tumor","enrollment":38},{"nctId":"NCT05880706","phase":"PHASE2","title":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-07-19","conditions":"Non-small Cell Lung Cancer","enrollment":198},{"nctId":"NCT06787664","phase":"PHASE2","title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-01-16","conditions":"Chordoma","enrollment":40},{"nctId":"NCT06598787","phase":"PHASE2","title":"A Study of BL-B01D1 in Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-10-17","conditions":"Recurrent Glioblastoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["iza-bren","izalontamab brengitecan","BMS-986507"],"phase":"phase_2","status":"active","brandName":"BL-B01D1 for Injection","genericName":"BL-B01D1 for Injection","companyName":"Sichuan Baili Pharmaceutical Co., Ltd.","companyId":"sichuan-baili-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BL-B01D1 for Injection is a drug that works by targeting a specific molecular pathway. Used for Phase 2 clinical trials for BL-B01D1 for Injection are ongoing, but specific indications are not publicly available..","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}